JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: JL1, a CD43 epitope and mucin family cell surface glycoprotein, is expressed on leukemic cells. An anti-JL1 antibody combined with a toxic substance can have targeted therapeutic effects against JL1-positive leukemia; however, JL1 expression on bone marrow (BM) lymphoma cells has not been assessed using flow cytometry. We investigated JL1 expression on BM lymphoma cells from patients with non-Hodgkin lymphoma (NHL) to assess the potential of JL1 as a therapeutic target. Methods: Patients with BM involvement of mature B-cell (N=44) or T- and natural killer (NK)-cell (N=4) lymphomas were enrolled from May 2015 to September 2016. JL1 expression on BM lymphoma cells was investigated using flow cytometry. Clinical, pathological, and cytogenetic characteristics, and treatment responses were compared according to JL1 expression status. Results: Of the patients with NHL and BM involvement, 37.5% (18/48) were JL1-positive. Among mature B-cell lymphomas, 100%, 38.9%, 33.3%, 100%, and 25.0% of Burkitt lymphomas, diffuse large B-cell leukemias, mantle cell leukemias, Waldenstrom macroglobulinemia, and other B-cell lymphomas, respectively, were JL1-positive. Three mature T- and NK-cell NHLs were JL1-positive. JL1 expression was associated with age (P=0.045), complete response (P=0.004), and BM involvement at follow-up (P=0.017), but not with sex, performance status, the B symptoms, packed marrow pattern, cytogenetic abnormalities, or survival. Conclusions: JL1 positivity was associated with superior complete response and less BM involvement in NHL following chemotherapy.
Abstract
Background: JL1, a CD43 epitope and mucin family cell surface glycoprotein, is expressed on leukemic cells. An anti-JL1 antibody combined with a toxic substance can have targeted therapeutic effects against JL1-positive leukemia; however, JL1 expression on bone marrow (BM) lymphoma cells has not been assessed using flow cytometry. We investigated JL1 expression on BM lymphoma cells from patients with non-Hodgkin lymphoma (NHL) to assess the potential of JL1 as a therapeutic target. Methods: Patients with BM involvement of mature B-cell (N=44) or T- and natural killer (NK)-cell (N=4) lymphomas were enrolled from May 2015 to September 2016. JL1 expression on BM lymphoma cells was investigated using flow cytometry. Clinical, pathological, and cytogenetic characteristics, and treatment responses were compared according to JL1 expression status. Results: Of the patients with NHL and BM involvement, 37.5% (18/48) were JL1-positive. Among mature B-cell lymphomas, 100%, 38.9%, 33.3%, 100%, and 25.0% of Burkitt lymphomas, diffuse large B-cell leukemias, mantle cell leukemias, Waldenstrom macroglobulinemia, and other B-cell lymphomas, respectively, were JL1-positive. Three mature T- and NK-cell NHLs were JL1-positive. JL1 expression was associated with age (P=0.045), complete response (P=0.004), and BM involvement at follow-up (P=0.017), but not with sex, performance status, the B symptoms, packed marrow pattern, cytogenetic abnormalities, or survival. Conclusions: JL1 positivity was associated with superior complete response and less BM involvement in NHL following chemotherapy.
참고문헌 (24)
- Park CS, "Diagnostic usefulness of monoclonal antibody for T lymphoblastic lymphoma", acute lymphoblastic leukemia-specific JL1 antigen in paraffin embedded tissue, 1999, pp.33, 1033~1038
- Shin YK, "Expression of leukemia-associated antigen, JL1, in bone marrow and thymus", Am J Pathol, 158, pp.1473~1480 (2001)
- Park SH, "JL1, a novel differentiation antigen of human cortical thymocyte", J Exp Med, 178, pp.1447~1451 (1993)
- Chung JK, "In vitro and in vivo properties of murine monoclonal antibody for a novel immature thymocyte-differentiated antigen, JL1", Nucl Med Biol, 24, pp.433~437 (1997)
- Park WS, "A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias", Leukemia, 12, pp.1583~1590 (1998)
- 김솟을, "Characterization of Two Novel mAbs Recognizing Different Epitopes on CD43", Immune Network, 14(3), pp.164~170 (2014), 대한면역학회
- Kim TJ, "Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia", J Korean Med Sci, 13, pp.455~458 (1998)
- Chung J, "Identification of antigenic peptide recognized by the anti-JL1 leukemia-specific monoclonal antibody from combinatorial peptide phage display libraries", J Cancer Res Clin Oncol, 128, pp.641~649 (2002)
- Park YS, "Expression of JL1 is an effective adjunctive marker of leukemia cutis", Arch Pathol Lab Med, 134, pp.95~102 (2010)
- Shin YK, "Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications", Cancer Immunol Immunother, 52, pp.506~512 (2003)
- Hwang I, "Expression of JL1 in Burkitt lymphoma is associated with improved overall survival", Virchows Arch, 459, pp.353~359 (2011)
- Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
- Oken MM, "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am J Clin Oncol, 5, pp.649~655 (1982)
- Dunleavy K, "Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma", N Engl J Med, 368, pp.1408~1416 (2013)
- Freedman AS, "DeVita, Hellman, and Rosenberg’s cancer: principles and practice of oncology", pp.1552~1587 (2015), Lippincott Williams & Wilkins
- Zelenetz AD, "Non-Hodgkin’s lymphomas, version 4.2014", J Natl Compr Canc Netw, 12, pp.1282~1303 (2014)
- Horwitz SM, "NCCN Guidelines Insights: Non-Hodgkin’s Lymphomas, Version 3.2016", J Natl Compr Canc Netw, 14, pp.1067~1079 (2016)
- El-Sayed AM, "Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry", Diagn Pathol, 3, pp.43~ (2008)
- Gruss HJ, "CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells", Leuk Lymphoma, 20, pp.397~409 (1996)
- You E, "JL1 antigen expression of leukemic cells in childhood acute leukemia", Haematologica, 102, pp.353~ (2017)
- Park HS, "Expression of JL1 antigen in acute leukemia and myelodysplastic syndrome", Blood, 126, pp.3826~ (2015)
- Patte C, "The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia", Blood, 97, pp.3370~3379 (2001)
- Zhao X, "JL1 is a cell surface molecule of acute leukemia blasts : potential for targeted immunotherapy", Cancer Res, 72, pp.2525~ (2012)
- Lee GK, "LFA-1-and ICAM-1-dependent homotypic aggregation of human thymocytes induced by JL1 engagement", Mol Cells, 9, pp.662~667 (1999)